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Toxicity of intraperitoneal bisulfite 
Studies were carried out in animals to investigate the toxicity of intraperitoneal bisulfite. 
The LDso (dose lethal to 50 per cent of the animals) for a single intraperitoneal injection 
of NaHS03 was calculated in the mouse, rat, rabbit, and dog. Studies indicated that the 
LDso dose was increased by dilution of the bisulfite. When sodium bisulfite was infused at 
a rate of 80 mg. of NaHS03 per kilogram per hour in the portal vein of dogs having bilateral 
ureteral ligations, bisulfite did not accumulate in the serum. Autoclaving dialysis fluid 
substantially reduced its bisulfite concentration. These studies suggest that NaHSO, in 
amounts usually added to dialysis solutions is unlikely to cause toxicity in patients undergoing 
peritoneal dialysis. 
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Sodium bisulfite (NaHSO,,) is added 
to parenteral solutions as an antioxidant. 
The peritoneal dialysis solutions used in 
our hospital contained 0.01 per cent 
NaHS03 in the 1.5 per cent glucose solu-
tion and 0.05 per cent NaHS03 in the 7 
per cent glucose solution. A patient given 
48 L. of dialysate daily, 12 of which are 
the 7 per cent glucose solution, would be 
exposed to 9,600 mg. of NaHS03 • The pos-
sibility of excessive administration of 
NaHS03 by this route warranted further 
investigation. The following studies in ani-
mals were carried out to determine the 
toxicity of peritoneal dialysis solutions con-
taining NaHS03 • 
Materials and methods 
Experiment I-Single-dose intraperi-
toneal LDso values of NaHSO j • The ani-
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mals used were male Swiss-Webster white 
mice weighing 19 to 25 grams; male 
Sprague-Dawley white rats weighing 235 
to 310 grams; male New Zealand white 
rabbits weighing 1.1 to 1.9 kilograms; and 
male and female mongrel dogs weighing 
7.8 to 15.8 kilograms. Animals were fasted 
24 hours prior to and during the day of 
injection. Four animals of each species 
were tested at each of four dosage levels. 
Mice were given 300 mg. per kilogram of 
body weightO of a 1.25 per cent NaHS03 
solution which was prepared immediately 
prior to injection in normal saline from 
which dissolved gases had been evacuated. 
Subsequent dose levels were each in-
creased by 50 per cent. The solutions given 
to the rats, rabbits, and dogs contained 25 
per cent NaHS03 similarly prepared. Rats 
were given the same dose as mice. Rabbits 
were given 133 mg. of NaHSOa per kilo-
gram and this dose level was increased 50 
per cent each time. Dogs were given 
# All doses throughout the rest of this paper are ex-
pressed in relation to body weight. 
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174 mg. of NaHSO, per kilogram with 
each subsequent dose increased 33 per 
cent. Animals were observed for 72 hours 
following injection. LD50 (dose lethal to 
50 per cent of the animals) values were 
calculated using the methods of Wei!.5 
Experiment II-Single-dose intraperi-
toneal LD50 values and the effect of the 
NaHS03 concentration. To investigate the 
effect of the N aHS03 concentration on 
the single-dose intraperitoneal LD50, male 
Sprague-Dawley rats weighing 350 to 400 
grams were used. Two concentrations of 
N aHS03 solution (5 and 1.25 per cent) 
were used to compare with the similarly 
prepared 25 per cent solution in Experi-
ment I. Four animals were injected with 
500 mg. of NaHS03 per kilogram and this 
dose level was increased by 33 per cent 
each of three additional doses. Animals 
were observed for 72 hours and LD50 
values were calculated. 
Experiment III-Measurement of bisul-
fite in biological fluids. A method was de-
vised to measure bisulfite in various bio-
logical solutions.G The solution containing 
bisulfite was placed in a Conway micro-
diffusion unit and acidified. The liberated 
S02 gas was trapped as H 2S03 in solution, 
oxidized by hydrogen peroxide to non-
volatile H 2S04 , then titrated with weak 
NaOH. This method was used in following 
serum bisulfite levels in Experiment IV 
and in determining bisulfite concentrations 
in dialysis solutions following autoclaving 
of six different bottles of 7 per cent glu-
cose dialysis fluid and six different bottles 
of 1.5 per cent glucose dialysis fluid. All 
determinations were run in triplicate. 
Experiment IV -Serum levels of bisul-
fite during continuous intravenous admin-
istration of solutions containing NaHSO s• 
Three mongrel dogs weighing 15 to 22 
kilograms were anesthetized with 30 mg. 
of pentobarbital per kilogram intrave-
nously, and their ureters were ligated by 
an abdominal approach. The splenic vein 
was cut free, a polyethylene catheter in-
serted, and freshly prepared solutions of 
NaHS03 in normal saline were infused at 
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a rate of 160 mg. per kilogram per hour 
for three hours. Immediately following this 
an infusion of 80 mg. of NaHS03 per kilo-
gram per hour was carried out for an addi-
tional three hours. Blood samples for bi-
sulfite analysis were drawn hourly from a 
catheter in the femoral artery. 
Results 
Experiment I. The single intraperitoneal 
dose LD50 values were determined to be 
675,498,300, and 244 mg. of NaHSO" per 
kilogram for the mouse, rat, rabbit, and 
dog, respectively (Table I). In all cases of 
death due to bisulfite, animals died within 
45 minutes of injection. The manner of 
death was best observed in the dog. The 
animals were extremely irritable and had 
clonic convulsions followed by respiratory 
instability with periods of apnea and cy-
anosis. Terminally, there was evidence of 
cardiovascular collapse associated with 
prolonged apnea. 
Experiment II. The LD50 in the rat for 
a single intraperitoneal dose was found to 
be dependent upon the concentration of 
NaHS03 in the injected solution. The LD50 
values were 498, 650, and 740 mg. of 
N aHS03 per kilogram with the 25, 5, and 
1.25 per cent NaHS03 solutions, respec-
tively (Table I). 
Experiment III. Dialysis fluid bisulfite 
concentrations determined following auto-
claving revealed a marked loss in the 
quantity of bisulfite in solution. The 7 per 
cent glucose solutions to which 500 mg. of 
NaHS03 per liter were added prior to 
autoclaving were found to contain 47 mg. 
of NaHS03 per liter (± S.E.M. of 5 mg. 
per liter) following autoclaving. The so-
lutions of 1.5 per cent glucose to which 
100 mg. of NaHS03 per liter had been 
added contained less than 25 mg. of 
NaHS03 per liter following autoclaving. 
(Reliability of this method for determining 
concentrations of N aHS03 less than 25 mg. 
per liter was not evaluated.) 
Experiment IV. The serum concentration 
of N aHS03 in the dog was determined 
during continuous splenic vein infusion of 
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Table I. Single-dose intraperitoneal LD50 studies of sodium bisulfite 
Mouse Rat Rabbit Dog 
1.25 em. 25 em. 5 em. 1.25 em. 25 em. 25 em. 
NaHSO, NaHSO, NaHSO, NaHSO, NaHSO, NaHSO, 
per 100 mi. per 100 mi. per 100 mI. per 100 mI. per 100 mI. per 100 mI. 
solution solution solution solution solution solution 
Dose I Dose Dose Dose Dose Dose (mg./ (mg./ (mg./ (mg./ (mg./ (mg./ 
Kg.) . Deaths Kg.) Deaths Kg.) Deaths Kg.) Deaths Kg.) Deaths Kg.) Deaths 
300 0/4 
450 0/4 
675 2/4 
300 0/4 
450 1/4 
675 4/4 
500 0/4 
654 4/4 
852 2/4 
500 0/4 
654 0/4 
852 3/4 
133 
200 
300 
450 
0/4 
2/4 
1/4 
3/4 
174 
230 
300 
393 
0/4 
1/4 
4/4 
4/4 1,012 4/4 1,012 4/4 1,125 4/4 1,125 4/4 
LD50: 
(mg./Kg.) 
95% conE-
dence range 
675 498 650 740 300 244 
of LD50: 534 to 853 406 to 610 558 to 756 650 to 845 183 to 491 213 to 279 
(mg./Kg.) 
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Fig. 1. The serum level of bisulfite (micrograms 
per milliliter) of three dogs during splenic vein 
infusion of NaHSO, is plotted against the hours 
of infusion. The infusion rate was 160 mg. of 
NaHSO, per kilogram per hour for the first three 
hours, then was reduced to 80 mg. of NaHSO, 
per kilogram per hour for the subsequent three 
hours. Dog B received a loading infusion of 240 
mg. of NaHSO, per kilogram per hour for two 
hours prior to the determination of the serum 
level at time zero. 
NaHS03 solutions. Following three hours 
of infusion at a rate of 160 mg. per kilo-
gram per hour, levels of 50 to 140 {Lg 
NaHS03 per milliliter of serum were re-
corded. In all three animals, a prompt fall 
in the serum concentration of bisulfite 
followed reduction in the infusion rate 
from 160 to 80 mg. of NaHS03 per kilo-
gram per hour. In one animal the serum 
bisulfite level after one hour fell to less 
than 25 {Lg per milliliter and in the other 
two to between 25 and 50 {Lg per milliliter 
(Fig. 1) . 
Discussion 
Little is known about the acute toxicity 
of N aHS03 , and even less about chronic 
toxicity. Hoppe and Goble3 found the 
single-dose intravenous LD50 of NaHS03 
to be 130 mg. per kilogram for the mouse, 
115 mg. per kilogram for the rat, 95 mg. 
per kilogram for the hamster, and 65 mg. 
per kilogram for the rabbit. The LD50 per 
kilogram decreases as animals increase in 
size. The toxicity of long-term exposure to 
bisulfite also was studied by Hoppe and 
Goble3 in the rabbit. The intravenous ad-
ministration of two thirds of the intra-
venous LDso dose, given every eight hours, 
five days a week, for three weeks, caused 
no deaths or pathophysiologic changes. 
Reiss and Gerstl4 investigated the intra-
peritoneal toxicity of NaHS03 in mice and 
reported that 0.18 mmole (18.54 mg.) or 
more given intraperitoneally caused death 
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within a few minutes. Two of Rve mice 
died after injection of 0.12 mmole (12.36 
mg.). Reiss and Gerst! found that bisul-
Rte in toxic doses had an immediate effect 
on the central nervous system as indicated 
by clonic convulsions, and on the cardio-
vascular center with rapid fall of blood 
pressure. 
Bhaghat and LocketP administered 
NaHS03 intraperitoneally to rats and 
found that a single injection of an isotonic 
solution of bisulRte equal to 3 per cent of 
body weight (585 mg. per kilogram) killed 
half of the animals. Toxic doses caused 
restlessness, cyanosis, prostration, and 
Rnally cardiovascular collapse with death 
within 35 minutes. Eighty to 90 per cent 
of a sublethal dose of NaHSOs could be 
accounted for as sulfate in the urine within 
four hours. 
The toxicity of peritoneal dialysis solu-
tions containing NaHS03 has been investi-
gated by Halaby and Mattocks.2 They ad-
ministered 7 per cent glucose dialysis solu-
tion containing S35-labeled bisulRte in 
single or repeated intraperitoneal doses to 
rabbits and demonstrated accumulation of 
S35 in the plasma. Following death of sev-
eral animals they concluded "that the use 
of 500 mg. per liter of NaHSOs in peri-
toneal dialysis fluids is dangerous and 
should be discontinued." To implicate 
NaHS03 toxicity in these deaths is un-
warranted since: (1) The total dose that 
the rabbits received varied from 16 to 
48 mg. per kilogram, which is less than 
the intravenous LD50 (65 mg.) reported 
by Hoppe and GobleS and considerably 
less than the intraperitoneal LD50 ( 300 
mg. ) reported here. (2) In the studies 
of Halaby and Mattocks2 animals died 
from 337 minutes to 30 hours following 
injection, much longer than the period 
of time for bisulRte to cause death re-
ported by others and conRrmed in this 
study. 1, 3, 4 (3) The SS5-labeled material 
that Halaby and Mattocks2 found ac-
cumulating in the serum of rabbits was 
not necessarily bisulRte. They did not 
distinguish that radioactivity due to bi-
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sulRte from that due to sulfate or other 
metabolites. Indeed, if one attempts to 
measure bisulRte in protein-free super-
natants prepared with 15 per cent tri-
chloracetic acid, there is poor and incon-
sistent bisulRte recovery.6 Much of the S35 
found in serum is probably in the form of 
sulfate, as there is rapid and relatively un-
limited ability to metabolize bisulfite to 
sulfate.1, 3 
As shown in Experiment II, when more 
dilute solutions are used, the bisulfite 
LD50 rises in rats. This indicates that with 
dilution a smaller amount of bisulfite 
moves across the peritoneum per unit time, 
therefore a greater total amount is re-
quired. The bisulRte concentrations used 
in these rats are several times greater than 
that present in the peritoneal dialysis fluid 
used in patients. 
Previous investigators have reported that 
bisulfite given intravenously in sublethal 
doses over long periods of time is non-
toxic.3 There is rapid conversion of bisul-
Rte to nontoxic substances.1 Peritoneal dia-
lysis is a chronic intermittent type of treat-
ment. In Experiment IV, bisulRte was in-
fused directly into the splenic vein to elim-
inate uncertainty regarding the rate of ab-
sorption of bisulRte from the peritoneal 
cavity. The ureters were ligated so that 
renal excretion would play a small role 
in protecting from bisulfite toxicity, since 
peritoneal dialysis is used in patients with 
greatly reduced renal function. Infusion of 
160 mg. of sodium bisulRte per kilogram 
per hour resulted in a constant, albeit 
small, increase in bisulfite concentration 
in the serum. This rising level of bisulfite 
was reversed by decreasing the infusion 
rate to 80 mg. per kilogram per hour, in-
dicating that in the dog the metabolism of 
sodium bisulRte to sulfate occurs at a rate 
of at least 80 mg. per kilogram of body 
weight per hour, at least four times the 
maximal conceivable exposure in a human 
undergoing chronic intermittent peritoneal 
dialysis (i.e., in a 50 kilogram patient re-
ceiving 2 L. of the 7 per cent glucose solu-
tion per hour, or 20 mg. of NaHSOg per 
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kilogram). Moreover, the rate of absorp-
tion and, therefore, the likelihood of tox-
icity in a man would be minimized by the 
more dilut~ bisulfite solutions used in peri-
toneal dialysis. 
Peritoneal dialysis solutions are usually 
sterilized by autoclaving. The amount of 
bisulfite remaining following autoclaving 
of the dialysis fluid is even less than 25 
per cent of the formulated amount. On the 
basis of these studies, it seems unlikely, 
therefore, that death due to bisulfite can 
result in man from chronic intermittent 
peritoneal dialysis. 
Conclusions 
Studies in animals on the toxicity of in-
traperitoneally administered bisulfite and 
determination of the rate of metabolism of 
the bisulfite given intravenously, coupled 
with the finding that the amount of bisul-
fite in peritoneal dialysis solutions is 
greatly reduced by autoclaving, suggest 
Clinical Pharmacology 
and Therapeutics 
that sodium bisulfite added to peritoneal 
dialysis solutions as an antioxidant is not 
likely to result in toxicity in patients. 
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